162 related articles for article (PubMed ID: 19664662)
1. The candidate sulfonated microbicide, PRO 2000, has potential multiple mechanisms of action against HIV-1.
Huskens D; Vermeire K; Profy AT; Schols D
Antiviral Res; 2009 Oct; 84(1):38-47. PubMed ID: 19664662
[TBL] [Abstract][Full Text] [Related]
2. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor.
Hatse S; Princen K; De Clercq E; Rosenkilde MM; Schwartz TW; Hernandez-Abad PE; Skerlj RT; Bridger GJ; Schols D
Biochem Pharmacol; 2005 Sep; 70(5):752-61. PubMed ID: 16011832
[TBL] [Abstract][Full Text] [Related]
3. HIV chemokine receptor inhibitors as novel anti-HIV drugs.
Princen K; Schols D
Cytokine Growth Factor Rev; 2005 Dec; 16(6):659-77. PubMed ID: 16005254
[TBL] [Abstract][Full Text] [Related]
4. R5- and X4-HIV-1 use differentially the endometrial epithelial cells HEC-1A to ensure their own spread: implication for mechanisms of sexual transmission.
Saïdi H; Magri G; Nasreddine N; Réquena M; Bélec L
Virology; 2007 Feb; 358(1):55-68. PubMed ID: 16934308
[TBL] [Abstract][Full Text] [Related]
5. Safety concerns for the potential use of cyanovirin-N as a microbicidal anti-HIV agent.
Huskens D; Vermeire K; Vandemeulebroucke E; Balzarini J; Schols D
Int J Biochem Cell Biol; 2008; 40(12):2802-14. PubMed ID: 18598778
[TBL] [Abstract][Full Text] [Related]
6. A killer mimotope with therapeutic activity against AIDS-related opportunistic micro-organisms inhibits ex-vivo HIV-1 replication.
Casoli C; Pilotti E; Perno CF; Balestra E; Polverini E; Cassone A; Conti S; Magliani W; Polonelli L
AIDS; 2006 Apr; 20(7):975-80. PubMed ID: 16603848
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 pathogenesis differs in rectosigmoid and tonsillar tissues infected ex vivo with CCR5- and CXCR4-tropic HIV-1.
Grivel JC; Elliott J; Lisco A; Biancotto A; Condack C; Shattock RJ; McGowan I; Margolis L; Anton P
AIDS; 2007 Jun; 21(10):1263-72. PubMed ID: 17545702
[TBL] [Abstract][Full Text] [Related]
8. Moesin is required for HIV-1-induced CD4-CXCR4 interaction, F-actin redistribution, membrane fusion and viral infection in lymphocytes.
Barrero-Villar M; Cabrero JR; Gordón-Alonso M; Barroso-González J; Alvarez-Losada S; Muñoz-Fernández MA; Sánchez-Madrid F; Valenzuela-Fernández A
J Cell Sci; 2009 Jan; 122(Pt 1):103-13. PubMed ID: 19066282
[TBL] [Abstract][Full Text] [Related]
9. The differential binding and activity of PRO 2000 against diverse HIV-1 envelopes.
Sachdev DD; Zerhouni-Layachi B; Ortigoza M; Profy AT; Tuen M; Hioe CE; Klotman ME
J Acquir Immune Defic Syndr; 2009 Jun; 51(2):125-9. PubMed ID: 19349871
[TBL] [Abstract][Full Text] [Related]
10. Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes.
Ketas TJ; Schader SM; Zurita J; Teo E; Polonis V; Lu M; Klasse PJ; Moore JP
Virology; 2007 Aug; 364(2):431-40. PubMed ID: 17428517
[TBL] [Abstract][Full Text] [Related]
11. Identification of a D-amino acid decapeptide HIV-1 entry inhibitor.
Boggiano C; Jiang S; Lu H; Zhao Q; Liu S; Binley J; Blondelle SE
Biochem Biophys Res Commun; 2006 Sep; 347(4):909-15. PubMed ID: 16854380
[TBL] [Abstract][Full Text] [Related]
12. PRO-2000, an antimicrobial gel for the potential prevention of HIV infection.
Fletcher PS; Shattock RJ
Curr Opin Investig Drugs; 2008 Feb; 9(2):189-200. PubMed ID: 18246522
[TBL] [Abstract][Full Text] [Related]
13. Raft localization of CXCR4 is primarily required for X4-tropic human immunodeficiency virus type 1 infection.
Kamiyama H; Yoshii H; Tanaka Y; Sato H; Yamamoto N; Kubo Y
Virology; 2009 Mar; 386(1):23-31. PubMed ID: 19178925
[TBL] [Abstract][Full Text] [Related]
14. Neutralising properties of peptides derived from CXCR4 extracellular loops towards CXCL12 binding and HIV-1 infection.
Chevigné A; Fievez V; Szpakowska M; Fischer A; Counson M; Plesséria JM; Schmit JC; Deroo S
Biochim Biophys Acta; 2014 May; 1843(5):1031-41. PubMed ID: 24480462
[TBL] [Abstract][Full Text] [Related]
15. CXCR4, inhibitors and mechanisms of action.
Liang X
Chem Biol Drug Des; 2008 Aug; 72(2):97-110. PubMed ID: 18624812
[TBL] [Abstract][Full Text] [Related]
16. Structure-function relationship of novel X4 HIV-1 entry inhibitors - L- and D-arginine peptide-aminoglycoside conjugates.
Hegde R; Borkow G; Berchanski A; Lapidot A
FEBS J; 2007 Dec; 274(24):6523-36. PubMed ID: 18028446
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4.
Bodart V; Anastassov V; Darkes MC; Idzan SR; Labrecque J; Lau G; Mosi RM; Neff KS; Nelson KL; Ruzek MC; Patel K; Santucci Z; Scarborough R; Wong RS; Bridger GJ; Macfarland RT; Fricker SP
Biochem Pharmacol; 2009 Oct; 78(8):993-1000. PubMed ID: 19540208
[TBL] [Abstract][Full Text] [Related]
18. Candidate polyanion microbicides inhibit HIV-1 infection and dissemination pathways in human cervical explants.
Fletcher PS; Wallace GS; Mesquita PM; Shattock RJ
Retrovirology; 2006 Aug; 3():46. PubMed ID: 16882346
[TBL] [Abstract][Full Text] [Related]
19. C-type lectin Mermaid inhibits dendritic cell mediated HIV-1 transmission to CD4+ T cells.
Nabatov AA; de Jong MA; de Witte L; Bulgheresi S; Geijtenbeek TB
Virology; 2008 Sep; 378(2):323-8. PubMed ID: 18597806
[TBL] [Abstract][Full Text] [Related]
20. SJ23B, a jatrophane diterpene activates classical PKCs and displays strong activity against HIV in vitro.
Bedoya LM; Márquez N; Martínez N; Gutiérrez-Eisman S; Alvarez A; Calzado MA; Rojas JM; Appendino G; Muñoz E; Alcamí J
Biochem Pharmacol; 2009 Mar; 77(6):965-78. PubMed ID: 19100719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
